MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE)
-- Pernix Therapeutics Holdings, Inc. (PTX),
a specialty pharmaceutical company, announced today that the
Company will report financial results for the third quarter and
nine months ended September 30, 2018, after the market close on
Thursday, November 8, 2018. Pernix management will also host
a conference call at 4:30 pm Eastern Time to discuss the
results.
| Date: | Thursday, November 8 |
| Time: | 4:30 PM ET |
| Toll free (U.S.): | 866-548-4713 |
| International: | 323-794-2093 |
| Conference ID: | 9549306 |
| Webcast: | http://public.viavid.com/index.php?id=131703 |
About Pernix Therapeutics Holdings, Inc.
Pernix Therapeutics Holdings, Inc. (the “Companyâ€) is the parent
company of Pernix Therapeutics, LLC, a specialty pharmaceutical
business focused on acquiring and commercializing prescription
drugs, primarily for the U.S. market. Pernix Therapeutics,
LLC is currently focused on the therapeutic areas of Pain and
Neurology, and has an interest in expanding into additional
specialty segments. Pernix Therapeutics, LLC promotes branded
products to physicians through its internal sales force. The
Company’s wholly-owned subsidiaries, Macoven Pharmaceuticals,
L.L.C., and Cypress Pharmaceuticals, Inc., market a portfolio of
generic products.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]